Author

Sarah McNamara

Observed name: McNamara, Sarah

Institution: Edinburgh Royal Infirmary

Observed institutions: Edinburgh Royal Infirmary, Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh

OpenAlex ID: A5087614124

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

2022 · Tom M. Quinn, Erin E. Gaughan, et al. · EBioMedicine · 54

A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS

2021 · Leila Reyes, Manuel A. Sanchez-Garcia, et al. · Wellcome Open Research · 47

A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS

2021 · Leila Reyes, Manuel A. Sanchez-Garcia, et al. · Wellcome Open Research · 45

First-in-human intrapulmonary intratarget microdosing of a novel dual inflammasome inhibitor of NLRP 1/ NLRP 3 in ex vivo human lungs and patients with interstitial lung disease

2026 · Tom Quinn, Feng Li, et al. · medRxiv

A retrospective study of crossover ambulatory oxygen walk testing in patients with fibrotic lung disease

2023 · Manjit K. Cartlidge, Hazel Wilkie, et al. · Respiratory Investigation

A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS

2021 · Reyes, Leila, Garcia, Manuel Alejandro Sanchez, et al. · Figshare

Works count: 6

Citation count: 146

H-index: 3

I10-index: 3